Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stéphane Picard(Inserm), François‐Xavier Mahon(Institut Bergonié)
Cited by 604
Related Papers
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
|Blood|2003|538
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
|New England Journal of Medicine|2010|385